Literature DB >> 9144499

Borrelia burgdorferi outer surface protein A (OspA) activates and primes human neutrophils.

T B Morrison1, J H Weis, J J Weis.   

Abstract

Lyme disease is caused by infection with the spirochete Borrelia burgdorferi and is characterized by bacterial persistence and inflammation of many host tissues. B. burgdorferi express outer surface lipoproteins, including OspA, with inflammatory properties that could contribute to the localized tissue inflammation. Neutrophils are the predominant infiltrate into the inflamed arthritic joints, and are crucial for controlling the spirochete infection. They may also contribute to the joint pathology associated with Lyme arthritis. This study examines the effect of OspA on the activities of the neutrophil. Picomolar concentrations of OspA induce surface markers associated with neutrophil activation: increased CD10 and CD11b expression; decreased CD62-L expression; and an increased adherence to extracellular matrix. These events were similar in kinetics and magnitude to those induced by the strong activators LPS and FMLP. Like LPS, OspA could prime neutrophils for FMLP-induced release of lysosomal granules and production of superoxide. Thus, models of Lyme arthritis should include the possible contribution of direct activation of neutrophils to both defense and disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144499

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

Review 1.  Borrelia burgdorferi and Treponema pallidum: a comparison of functional genomics, environmental adaptations, and pathogenic mechanisms.

Authors:  S F Porcella; T G Schwan
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Complement receptor 3 binds the Borrelia burgdorferi outer surface proteins OspA and OspB in an iC3b-independent manner.

Authors:  Rodolfo C Garcia; Rossella Murgia; Marina Cinco
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Lyme arthritis: current concepts and a change in paradigm.

Authors:  Dean T Nardelli; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

4.  Induction of pro- and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is mediated by CD14.

Authors:  G H Giambartolomei; V A Dennis; B L Lasater; M T Philipp
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

5.  Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex.

Authors:  Diana Rose E Ranoa; Stacy L Kelley; Richard I Tapping
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

6.  Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice.

Authors:  Joseph Kuo; Dean T Nardelli; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

7.  E and P selectins are not required for resistance to severe murine lyme arthritis.

Authors:  K P Seiler; Y Ma; J H Weis; P S Frenette; R O Hynes; D D Wagner; J J Weis
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  CXCL11 is involved in leucocyte recruitment to the central nervous system in neuroborreliosis.

Authors:  Tobias A Rupprecht; Uwe Koedel; Beatrice Muhlberger; Bettina Wilske; Adriano Fontana; Hans-Walter Pfister
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

9.  CXCR2 blockade influences Anaplasma phagocytophilum propagation but not histopathology in the mouse model of human granulocytic anaplasmosis.

Authors:  Diana G Scorpio; Mustafa Akkoyunlu; Erol Fikrig; J Stephen Dumler
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

10.  Toll-like receptors: insights into their possible role in the pathogenesis of lyme neuroborreliosis.

Authors:  Andrea L F Bernardino; Tereance A Myers; Xavier Alvarez; Atsuhiko Hasegawa; Mario T Philipp
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.